The potential role of adjunctive bone-protective therapies - including calcium and vitamin D supplementation, weight-bearing exercise, and, in selected high-risk cases, pharmacologic agents such as bisphosphonates - should be considered on an individual basis, though no evidence specifically addresses this question in MC4R -deficient patients
Follow-up then supports titration and side-effect management
Key Clinical Applications 1
Benson, who on the advice of counsel declined to comment, told a local TV station in January, I dont know that Ive ever felt that way in my life
Market Size & Forecast Major Players Companies such as Novo Nordisk (DK), Eli Lilly (US), Sanofi (FR), Boehringer Ingelheim (DE), AstraZeneca (GB), Merck & Co